Review

. 2018 Sep 3;23(9):2238.

doi: 10.3390/molecules23092238.

Use of Polyamidoamine Dendrimers in Brain Diseases

Maria Florendo^{1

2}, Alexander Figacz^{3

4}, Bhairavi Srinageshwar^{5

6

7}, Ajit Sharma⁸, Douglas Swanson⁹, Gary L Dunbar^{10

11

12

13}, Julien Rossignol^{14

15

16}

Affiliations

¹ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. flore1mv@cmich.edu.
² Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. flore1mv@cmich.edu.
³ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. figac1am@cmich.edu.
⁴ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. figac1am@cmich.edu.
⁵ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁶ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁷ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁸ Department of Chemistry & Biochemistry, Central Michigan University, Mt. Pleasant, MI 48859, USA. sharm1a@cmich.edu.
⁹ Department of Chemistry & Biochemistry, Central Michigan University, Mt. Pleasant, MI 48859, USA. swans1d@cmich.edu.
¹⁰ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹¹ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹² Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹³ Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA. dunba1g@cmich.edu.
¹⁴ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.
¹⁵ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.
¹⁶ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.

PMID: 30177605
PMCID: PMC6225146
DOI: 10.3390/molecules23092238

Review

Use of Polyamidoamine Dendrimers in Brain Diseases

Maria Florendo et al. Molecules. 2018.

. 2018 Sep 3;23(9):2238.

doi: 10.3390/molecules23092238.

Authors

Maria Florendo^{1

2}, Alexander Figacz^{3

4}, Bhairavi Srinageshwar^{5

6

7}, Ajit Sharma⁸, Douglas Swanson⁹, Gary L Dunbar^{10

11

12

13}, Julien Rossignol^{14

15

16}

Affiliations

¹ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. flore1mv@cmich.edu.
² Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. flore1mv@cmich.edu.
³ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. figac1am@cmich.edu.
⁴ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. figac1am@cmich.edu.
⁵ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁶ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁷ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. srina1b@cmich.edu.
⁸ Department of Chemistry & Biochemistry, Central Michigan University, Mt. Pleasant, MI 48859, USA. sharm1a@cmich.edu.
⁹ Department of Chemistry & Biochemistry, Central Michigan University, Mt. Pleasant, MI 48859, USA. swans1d@cmich.edu.
¹⁰ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹¹ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹² Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu.
¹³ Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA. dunba1g@cmich.edu.
¹⁴ College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.
¹⁵ Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.
¹⁶ Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. rossi1j@cmich.edu.

PMID: 30177605
PMCID: PMC6225146
DOI: 10.3390/molecules23092238

Abstract

Polyamidoamine (PAMAM) dendrimers are one of the smallest and most precise nanomolecules available today, which have promising applications for the treatment of brain diseases. Each aspect of the dendrimer (core, size or generation, size of cavities, and surface functional groups) can be precisely modulated to yield a variety of nanocarriers for delivery of drugs and genes to brain cells in vitro or in vivo. Two of the most important criteria to consider when using PAMAM dendrimers for neuroscience applications is their safety profile and their potential to be prepared in a reproducible manner. Based on these criteria, features of PAMAM dendrimers are described to help the neuroscience researcher to judiciously choose the right type of dendrimer and the appropriate method for loading the drug to form a safe and effective delivery system to the brain.

Keywords: DNA delivery; PAMAM dendrimers; blood-brain barrier; drug delivery; nanoparticles; neurodegenerative diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
(A) A G4 polyamidoamine (PAMAM) dendrimer [37].(B) Every component of a dendrimer can be controlled including its core composition, size, shape, and surface (adapted from [38]).

See this image and copyright information in PMC

Cited by

Polyamide/Poly(Amino Acid) Polymers for Drug Delivery.
Boddu SHS, Bhagav P, Karla PK, Jacob S, Adatiya MD, Dhameliya TM, Ranch KM, Tiwari AK. Boddu SHS, et al. J Funct Biomater. 2021 Oct 8;12(4):58. doi: 10.3390/jfb12040058. J Funct Biomater. 2021. PMID: 34698184 Free PMC article. Review.
Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders.
Tyagi K, Rai P, Gautam A, Kaur H, Kapoor S, Suttee A, Jaiswal PK, Sharma A, Singh G, Barnwal RP. Tyagi K, et al. Eur J Med Res. 2023 Aug 30;28(1):307. doi: 10.1186/s40001-023-01293-2. Eur J Med Res. 2023. PMID: 37649125 Free PMC article. Review.
Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.
Mroziak M, Kozłowski G, Kołodziejczyk W, Pszczołowska M, Walczak K, Beszłej JA, Leszek J. Mroziak M, et al. Biomedicines. 2024 Aug 20;12(8):1899. doi: 10.3390/biomedicines12081899. Biomedicines. 2024. PMID: 39200363 Free PMC article. Review.
Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies.
Arbez-Gindre C, Steele BR, Micha-Screttas M. Arbez-Gindre C, et al. Pharmaceutics. 2023 Mar 10;15(3):898. doi: 10.3390/pharmaceutics15030898. Pharmaceutics. 2023. PMID: 36986759 Free PMC article. Review.
Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies.
Abaidullah N, Muhammad K, Waheed Y. Abaidullah N, et al. AAPS PharmSciTech. 2025 Mar 4;26(3):74. doi: 10.1208/s12249-025-03063-1. AAPS PharmSciTech. 2025. PMID: 40038143 Review.

See all "Cited by" articles

References

1. Huebner E.A., Strittmatter S.M. Axon regeneration in the peripheral and central nervous systems. Results Probl. Cell Differ. 2009;48:339–351. doi: 10.1007/400_2009_19. - DOI - PMC - PubMed
1. Young A.B. Four decades of neurodegenerative disease research: How far we have come! J. Neurosci. 2009;29:12722–12728. doi: 10.1523/JNEUROSCI.3767-09.2009. - DOI - PMC - PubMed
1. Holland E.C. Glioblastoma multiforme: The terminator. Proc. Natl. Acad. Sci. USA. 2000;97:6242–6244. doi: 10.1073/pnas.97.12.6242. - DOI - PMC - PubMed
1. Kannan R.M., Nance E., Kannan S., Tomalia D.A. Emerging concepts in dendrimer-based nanomedicine: From design principles to clinical applications. J. Intern. Med. 2014;276:579–617. doi: 10.1111/joim.12280. - DOI - PubMed
1. Otto D.P., de Villiers M.M. Poly(amidoamine) Dendrimers as a Pharmaceutical Excipient. Are We There yet? J. Pharm. Sci. 2018;107:75–83. doi: 10.1016/j.xphs.2017.10.011. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Use of Polyamidoamine Dendrimers in Brain Diseases

Affiliations

Use of Polyamidoamine Dendrimers in Brain Diseases

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical